STUDY SEARCH RESULTS

2 studies found for your search request:  7902-001

Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinom...
Condition: Endometrial Neoplasms
Minimum Age: 18 years, Maximum Age: N/A
Gender: Female
Study ID: NCT03884101
Status: Active, not recruiting

Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinom...
Condition: Endometrial Neoplasms
Minimum Age: 18 years, Maximum Age: N/A
Gender: Female
Study ID: NCT04865289
Status: Active, not recruiting




Copyright © 2024 · Merck & Co., Inc., Rahway, NJ, USA, and its affiliates. All rights reserved. · This site is intended only for residents of the United States.
Cookie Preferences  Privacy  Terms of Use  U.S. Corporate Site